Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00754936 · ClinicalTrials.gov registry record · NA

Treatment Response of Geriatric Depression

A NA study, sponsored by Weill Medical College of Cornell University.

Completed
Registry status
NA
Development phase
106
Enrollment target

NCT00754936: Completed NA study, sponsored by Weill Medical College of Cornell University.

NCT00754936 is a NA study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 106 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00754936, a NA study, has completed, sponsored by Weill Medical College of Cornell University.

COMPLETED
Registry status
NA
Development phase
106 participants
Enrollment target

Study Summary

The purpose of this study is to examine the relationship between brain electrical activity in elderly depressed patients and response to antidepressant medication treatment. Elderly patients with depression will be treated for 12 weeks with an antidepressant medication commonly used in clinical practice called escitalopram (Lexapro). Brain electrical activity will be assessed using electrophysiological tests. Researchers are interested in whether the brain electrical activity of elderly people with depression before they start the medication can tell us who amongst them will improve with antidepressant treatment and to what extent. They will also determine whether patients' brain electrical activity during the 12 weeks of medication treatment will change in any way and whether this change will be linked with a change in the severity of their depression. Researchers hope that information gained from this study will help to better understand the brain processes associated with depression and its successful treatment.

Primary Outcome

A published and widely used scale for measuring severity of depression. Montgomery Asberg Depression Rating Scale scores can range from 0-60. Higher scores indicate greater severity of depression. Total scores are reported with no subscales.

Interventions

  • DRUG Escitalopram

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2007-05
Est. Completion 2015-05
Phase NA

What the finished NCT00754936 record still lists

NCT00754936 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 1 intervention - of which Escitalopram is the first listed.

NCT00754936 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00754936 about?

NCT00754936 is a clinical study titled "Treatment Response of Geriatric Depression". The purpose of this study is to examine the relationship between brain electrical activity in elderly depressed patients and response to antidepressant medication treatment. Elderly patients with depression will be treated for 12 weeks with an antidepressant medication commonly used in clinical prac...

What is the current status of trial NCT00754936?

This trial is currently completed. It is a NA study. The enrollment target is 106 participants. The study started on 2007-05. Estimated completion is 2015-05.

What interventions are being tested in trial NCT00754936?

The interventions under investigation include: Escitalopram (DRUG).

Who is sponsoring clinical trial NCT00754936?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00754936's enrollment target sits among peer trials

106 830th of 2000 higher than 1,167 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03181048 · 106 participants · NA

    Clinical Trial of Concomitant Hip Arthroscopy During PAO

  • NCT04682158 · 106 participants · Phase 2

    Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

  • NCT04724018 · 106 participants · Phase 1

    Sacituzumab Govitecan Plus EV in Metastatic UC

  • NCT04798274 · 106 participants · NA

    Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00754936, the US trial registry maintained by the National Library of Medicine. NCT00754936 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.